Eli Lilly’s Bamlanivimab Can Prevent Covid Infection, Clinical Trial Shows
It's the first time an antibody treatment has prevented infection. Eli Lilly's chief scientific officer told Stat: "Of course, I think the vaccines are more effective ... and likely longer lasting. So this should not be seen in any way as competition to vaccines. It should be for when it’s too late, when there’s an outbreak and people are getting exposed and there’s not going to be time for a vaccine to work.”
Stat:
Eli Lilly Says Its Monoclonal Antibody Prevented Covid-19 In Clinical Trial
Eli Lilly said Thursday that its monoclonal antibody prevented Covid-19 infections in nursing home residents and staff in a clinical trial, the first time such a treatment has been shown to prevent infection. Lilly released the results in a press release, although it said that it would publish the data in a research paper as quickly as possible. (Herper, 1/21)
AP:
Lilly: Drug Can Prevent COVID-19 Illness In Nursing Homes
Drugmaker Eli Lilly said Thursday its antibody drug can prevent COVID-19 illness in residents and staff of nursing homes and other long-term care locations. It’s the first major study to show such a treatment may prevent illness in a group that has been devastated by the pandemic. Residents and staff who got the drug had up to a 57% lower risk of getting COVID-19 compared to others at the same facility who got a placebo, the drugmaker said. Among nursing home residents only, the risk was reduced by up to 80%. (Murphy, 1/21)
The Hill:
Eli Lilly Says Antibody Therapy Prevented COVID-19 In Nursing Homes
Eli Lilly on Thursday said its antibody COVID-19 treatment significantly reduced the risk of nursing home residents and staff contracting symptomatic COVID-19 in a clinical trial. The company announced the results of its trial in a press release, but said they will be submitted for publication in a peer-reviewed clinical journal. (Weixel, 1/21)
The Wall Street Journal:
Lilly Antibody Drug Prevents Covid-19 In Nursing Homes, Study Finds
Eli Lilly & Co. said its antibody-based drug prevented Covid-19 among many residents and staff of nursing homes and assisted-living facilities, results that point to the drug complementing vaccines while inoculations increase. The drug, called bamlanivimab, reduced the risk of both staff and residents getting sick with Covid-19 by about 57% compared with a placebo eight weeks after receiving doses, Lilly said Thursday. The effect was more pronounced among residents, the company said, an 80% reduction in risk of Covid-19. (Loftus, 1/21)
